Arrowsmith is a drug discovery startup developing “phage therapy,” an innovative treatment for drug-resistant bacterial infections and difficult-to-treat bacterial infections, using bacteriophages, which are viruses that prey on bacteria.
/
Company name
Arrowsmith Inc.
Type of business
Medical(medical devices, drug discovery)
Representatives
Hiroki Ando
Establishing a company
February 2025
Investment announcement date
August 2025
Capitalist
Jun Hayashi
HP
Phasing
Early
2025
08
20
JIC Venture Growth Investments has acquired the shares in "Arrowsmith Inc.", which provides phage therapy
back
